ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Antibodies"

  • Abstract Number: 2318 • 2017 ACR/ARHP Annual Meeting

    Measurement of Serum Infliximab and Antibody Levels As an Adjunct to Clinical Decision Making Regarding Infliximab Therapy

    Eileen Pagano1, Myriam Kline2 and B. Anne Eberhard3, 1Pediatric Rheumatology, Cohen Children's Medical Center of New York, New Hyde Park, NY, 2Biostatistics Unit, Feinstein Institute for Medical Research, Northwell Health, Manhasset, NY, 3Pediatric Rheumatology, Cohen Children's Medical Center of New York, Lake Success, NY

    Background/Purpose: Infliximab (IFX) is a chimeric monoclonal antibody against tumor necrosis factor alpha (TNF-a). It is known to be effective and often used in the…
  • Abstract Number: 2876 • 2017 ACR/ARHP Annual Meeting

    Analysis of Autoantibody Reactivity to the Complete Human Peptidome By Phage Immunoprecipitation Sequencing Does Not Identify a Predominant Novel Autoantibody in Sjogren’s Syndrome

    Tiezheng Yuan1, Michelle Petri2, Alan N. Baer3 and H. Benjamin Larman1, 1Pathology (Immunology), Johns Hopkins University School of Medicine, Baltimore, MD, 2Medicine (Rheumatology), Division of Rheumatology, Johns Hopkins University School of Medicine, MD, USA, Baltimore, MD, 3Medicine (Rheumatology), Johns Hopkins University School of Medicine, Baltimore, MD

    Background/Purpose: An unbiased and comprehensive approach to the analysis of Sjögren’s syndrome (SS) antibody repertoires would provide important data on its pathogenesis. Phage ImmunoPrecipitation sequencing…
  • Abstract Number: 132 • 2017 ACR/ARHP Annual Meeting

    Occupational Physical Workload and Development of Anti-Collagen Type II Antibodies in Rheumatoid Arthritis Patients

    Pingling Zeng1, Lars Alfredsson2, Lars Klareskog3, Mohammed Mullazehi4, Saedis Saevarsdottir5, Camilla Bengtsson6 and Johan Rönnelid7, 1Institute of Environmental Medicine, Institute of Environmental Medicine, Karolinska Institute, Stockholm, Sweden, Stockholm, Sweden, 2The Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden, 3Dept. of Medicine, Rheumatology Unit, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden, 4Department of Immunology, Genetics and Pathology,Uppsala University, Uppsala, Sweden, Uppsala, Sweden, 5Karolinska Institute and Karonlinska University Hospital, Stockholm, Sweden, 6Inst of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden, 7Department of Immunology Genetics and Pathology, Uppsala University, Uppsala, Sweden

    Background/Purpose: We have previously observed an association between exposure to occupational physical workload (PW) and risk of developing rheumatoid arthritis (RA)[1].We posit that PW could…
  • Abstract Number: 521 • 2017 ACR/ARHP Annual Meeting

    Update on the Clinical Phase 1 and Phase 2 Trials Investigating the Fully Human Immunocytokine Dekavil (F8IL10) in Patients with Rheumatoid Arthritis

    Mauro Galeazzi1, Gian Domenico Sebastiani2, Jürgen Wollenhaupt3, Jean Dudler4, Christof Specker5, Reinhard Voll6, Pascal Zufferey7, Piercarlo Sarzi Puttini8, Ombretta Viapiana9 and Franziska Bootz10, 1Rheumatology, University Hospital of Siena, Siena, Italy, 2Rheumatology, San Camillo Forlanini Hospital, Roma, Italy, 3Division of Reheumatology, Schoen-Klinik Hamburg-Eilbek Teaching Hospital of the University of Hamburg, Hamburg, Germany, 4Rheumatology, Cantonal Hospital Fribourg, Fribourg, Switzerland, 5Rheumatology, St. Josef Krankenhaus, Universitätsklinikum Essen, Esssen, Germany, 6Clinic for Rheumatology and Clinical Immunology, Medical Center University of Freiburg, Freiburg, Germany, 7Department of Rheumatology, University Hospital Lausanne, Lausanne, Switzerland, 8Rheumatology, Luigi Sacco Hospital, Milan, Italy, 9University Hospital Verona, Verona, Italy, 10Clinical Department, Philochem AG (Philogen Group), Otelfingen, Switzerland

    Background/Purpose: The antibody-based targeted pharmacodelivery of cytokines by means of immunocytokines has the potential to enhance therapeutic activity at the site of disease while sparing…
  • Abstract Number: 944 • 2017 ACR/ARHP Annual Meeting

    Long-Term Survival and Follow-up of Anti-Th/to Antibody Positive Systemic Sclerosis Patients

    Devon Charlton1, Maureen Laffoon2, Thomas A. Medsger Jr.3 and Robyn T. Domsic4, 1Division of Rheumatology and Clinical Immunology, University of Pittsburgh Medical Center, Pittsburgh, PA, 2Rheumatology, University of Pittsburgh Medical Center, Pittsburgh, PA, 3Department of Medicine/Rheumatology, University of Pittsburgh, Pittsburgh, PA, 4Medicine - Rheumatology, University of Pittsburgh, Pittsburgh, PA

    Background/Purpose: Anti-Th/To antibody is an autoantibody associated with systemic sclerosis (SSc), occurring in 5-10% of patients. To date, only relatively small case series have described…
  • Abstract Number: 1437 • 2016 ACR/ARHP Annual Meeting

    Netrin-1 and Its Receptor Unc5b Are Novel Targets for the Treatment of Inflammatory Arthritis

    Aranzazu Mediero1, Tuere Wilder2, Bhama Ramkhelawon3, Kathryn Moore3 and Bruce Cronstein4, 1Medicine, Divison of Translational Medicine, NYU School of Medicine, New York City, NY, 2Department of Medicine, Division of Rheumatology, NYU School of Medicine, New York, NY, 3Leon H. Charney Division of Cardiology, Department of Medicine,, NYU School of Medicine, New York, NY, 4Medicine, Division of Rheumatology, NYU School of Medicine, New York, NY

    Background/Purpose:  Rheumatoid arthritis (RA) is an autoimmune disease that causes chronic inflammation and destruction of joints. Netrin-1, a laminin-like matrix protein that acts as a…
  • Abstract Number: 1667 • 2016 ACR/ARHP Annual Meeting

    Diagnostic Value of Anti-CD74 Antibodies in Axial Spondyloarthritis: Results from a Population with Low HLA-B27 Prevalence Background

    Nelly Ziade1, Fouad Fayad1, Iyad Mallak2, Georges Merheb3, Torsten Witte4 and Xenofon Baraliakos5, 1Rheumatology, Hotel Dieu de France Hospital and Saint Joseph University, Beirut, Lebanon, 2Radiology, Hotel-Dieu de France and Saint-Joseph University, Beirut, Lebanon, 3Internal Medicine, Notre Dame des Secours University Hospital, Jbeil, Lebanon, 4Department of Clinical Immunology and Rheumatology, Hannover Medical School, Hannover, Germany, 5Rheumatology, Rheumazentrum Ruhrgebiet, Herne, Germany

    Background/Purpose: Axial spondyloarthritis (axSpA) is still frequently diagnosed late and its pathogenesis is still unclear. Although a strong genetic association of axSpA with HLA-B27 is…
  • Abstract Number: 1876 • 2016 ACR/ARHP Annual Meeting

    Prevalence of Anti-RNA Polymerase III IgG Antibody in a Cohort of Patients with Delayed Wound Healing

    Christian Geier1, Sean McNish2 and Victoria K. Shanmugam2, 1Department of Medicine, The George Washington University, Washington, DC, 2Division of Rheumatology, The George Washington University, Washington, DC

    Prevalence of Anti-RNA Polymerase III IgG Antibody in a Cohort of Patients with Delayed Wound Healing Background/Purpose: Anti-RNA polymerase III IgG antibody (Pol3) is associated…
  • Abstract Number: 2454 • 2016 ACR/ARHP Annual Meeting

    Cohort of Pregnant Women with Ro/La Antibodies: Risk of Fetal Third Degree Atrioventricular Block and Use of Hydroxychloroquine

    Florencia Beatriz Mollerach1, Marina Scolnik2, Luis J. Catoggio2 and Enrique R. Soriano1, 1Rheumatology Unit, Internal Medicine Service, Hospital Italiano de Buenos Aires, Instituto Universitario Hospital Italiano de Buenos Aires, and Fundacion PM Catoggio, Buenos Aires, Argentina, 2Rheumatology Unit, Internal Medicine Service, Hospital Italiano de Buenos Aires, Instituto Universitario Hospital Italiano de Buenos Aires, and Fundacion PM Catoggio, Argentina., Buenos Aires, Argentina

    Background/Purpose: Third degree atrioventricular block(AVB), a rare congenital complication, duplicate-triplicate frequency up to 2% when Ro/La maternal antibodies are present. Incidence rises to 17-20% in…
  • Abstract Number: 2535 • 2016 ACR/ARHP Annual Meeting

    Effect of Methotrexate in the Presence of Drug and the Appearance of Antibodies Against Tumour Necrosis Factor Inhibitors in Patients with Rheumatoid Arthritis

    Chamaida Plasencia-Rodriguez1, Ana Martínez2, Alejandro Villalba3, Teresa Jurado4, Eva Olariaga-Merida5, Araceli Mezcua6, Diana Peiteado3, Gema Bonilla3, Laura Nuño3, Alejandro Balsa1 and Dora Pascual-Salcedo2, 1Instituto de Investigación Hospital Universitario La Paz (IDIPAZ), Madrid, Spain, 2Immunology Unit, La Paz University Hospital-Immunology, Madrid, Spain, 3Rheumatology, Hospital La Paz - IdiPaz, Madrid, Spain, 4Immunology Unit, La Paz University Hospital-IdiPaz, MADRID, Spain, 5Immunology, University Hospital La Paz, Madrid, Spain, 6Immunology Unit, La Paz University Hospital, Madrid, Spain

    Background/Purpose: Several factors influence pharmacokinetics of TNFinhibitors (TNFi). One relevant factor is the formation of anti drug- antibodies (ADA) associated with low drug levels and…
  • Abstract Number: 2682 • 2016 ACR/ARHP Annual Meeting

    How Does Primary Sjogren Syndrome Present in Biopsy-Proven Patients without Circulating Ro/La Autoantibodies? Characteristics at Diagnosis of 2073 Patients from the SjöGren Big Data Project

    Pilar Brito-Zerón1,2,3, Nihan Acar-Denizli4, Margit Zeher5, Astrid Rasmussen6, Raphaele Seror7, Elke Theander8, Xiaomei Li9, Chiara Baldini10, Jacques-Eric Gottenberg11, Debashish Danda12, Luca Quartuccio13, Roberta Priori14,15, Gabriela Hernandez-Molina16, Aike A. Kruize17, Valeria Valim18, Marika Kvarnström19, Damien Sene20, Roberto Gerli21, Sonja Praprotnik22, David A. Isenberg23, Roser Solans24, Maureen Rischmueller25, Seung-Ki Kwok26, Gunnel Nordmark27, Yasunori Suzuki28, Roberto Giacomelli29, Valerie Devauchelle-Pensec30, Michele Bombardieri31, Benedikt Hofauer32, Hendrika Bootsma33, Johan G. Brun34, Guadalupe Fraile35, Steven E. Carsons36, Tamer Gheita37, Jacques Morel38, Cristina F. Vollenweider39, Fabiola Atzeni40, Soledad Retamozo41, Ildike-Fanny Horvath5, Kathy Sivils6, Thomas Mandl42,43, Pulukool Sandhya12, Salvatore De Vita44, Jorge Sánchez-Guerrero45, Eefje van der Heijden17, Virginia Moça Trevisano46, Marie Wahren-Herlenius19, Xavier Mariette7, Manuel Ramos-Casals3,47,48 and EULAR-SS Task Force Big Data Consortium (ASSES, GEAS-SEMI, EULAR), 1Autoimmune Diseases Unit, Department of Medicine, Hospital CIMA- Sanitas, Barcelona., Bacelona, Spain, 2Laboratory of Systemic Autoimmune Diseases “Josep Font”, CELLEX, Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Department of Systemic Autoimmune Diseases, ICMID, Hospital Clinic, Barcelona, Barcelona, Spain, 3Laboratory of Systemic Autoimmune Diseases “Josep Font”, CELLEX, Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Department of Systemic Autoimmune Diseases, ICMID, Hospital Clinic, Barcelona, Spain, Barcelona, Spain, 4Department of Statistics, Faculty of Science and Letters, Mimar Sinan Fine Arts University, Turkey, Istabul, Turkey, 5Division of Clinical Immunology, Faculty of Medicine, University of Debrecen, Debrecen, Hungary., Debrecen, Hungary, 6Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, USA, Oklahoma City, OK, 7Center for Immunology of Viral Infections and Autoimmune Diseases, Assistance Publique – Hôpitaux de Paris, Hôpitaux Universitaires Paris-Sud, Le Kremlin-Bicêtre, Université Paris Sud, INSERM, Paris, France, Paris, France, 8Department of Rheumatology, Malmö University Hospital, Lund University, Sweden, Malmö, Sweden, 9Department of Rheumatology and Immunology, Anhui Medical University Affiliated Provincial Hospital, China, Hefei, Anhui, China, 10Rheumatology Unit, University of Pisa, Italy, Pisa, Italy, 11Department of Rheumatology, Strasbourg University Hospital, Université de Strasbourg, CNRS, Strasbourg, France, Strasbourg, France, 12Clinical Immunology & Rheumatology, Christian Medical College, Vellore, India, Vellore, India, 13Rheumatology Clinic, DSMB, University of Udine, Udine, Italy, Udine, Italy, 14Rheumatology Unit, Sapienza University of Rome, Rome, Italy, 15Department of Internal Medicine and Medical Specialties, Sapienza University, Rome, Italy, 16Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico City, Mexico, 17Department of Rheumatology & Clinical Immunology, Medical Center Utrecht, The Netherlands, Utrecht, Netherlands, 18Rheumatology, Department of Medicine, Universidade Federal do Espírito Santo, Vitória, Brazil, Vitória, Brazil, 19Department of Medicine, Solna, Unit of Experimental Rheumatology, Karolinska Institutet, and Karolinska University Hospital, Stockholm, Sweden, Stockholm, Sweden, 20Service de Médecine Interne 2, Hôpital Lariboisière, Université Paris VII, Assistance Publique-Hôpitaux de Paris, 2, Paris, France, Paris, France, 21Clinical and Experimental Medicine, Rheumatology Unit, University of Perugia, Italy, Perugia, Italy, 22Department of Rheumatology, University Medical Centre Ljubljana, Slovenia, Ljubljana, Slovenia, 23Centre for Rheumatology Research, University College Hospital London, UK, London, United Kingdom, 24Autoimmune Systemic Diseases Unit, Department of Internal Medicine, Hospital Vall d'Hebron, Autonomous University of Barcelona, Spain, Barcelona, Spain, 25Department of Rheumatology, School of Medicine, The University of Western Australia, Crawley, Australia, Crawley, Australia, 26[email protected], Division of Rheumatology, Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul, South Korea, 27Rheumatology, Department of Medical Sciences, Uppsala University, Sweden, Uppsala, Sweden, 28Division of Rheumatology , Kanazawa University Hospital , Kanazawa , Ishikawa , Japan, Ishikawa, Japan, 29Clinical Unit of Rheumatology, University of l'Aquila, School of Medicine, L'Aquila, Italy, L'Aquila, Italy, 30Department of Rheumatology, Brest University Hospital, Brest, France, Brest, France, 31Willian Harvey Research Institute, Centre for Experimental Medicine and Rheumatology, QMUL, UK, London, United Kingdom, 32Hals-Nasen-Ohrenklinik und Poliklinik, Technische Universität München, München, Germany, München, Germany, 33Rheumatology and Clinical Immunology, University of Groningen, University Medical Center Groningen, The Netherlands, Groningen, Netherlands, 34Department of Clinical Science, University of Bergen. Department of Rheumatology, Haukeland University Hospital, Bergen, Norway, Bergen, Norway, 35Department of Internal Medicine, Hospital Ramón y Cajal, Madrid, Spain, Madrid, Spain, 36Division of Rheumatology, Allergy and Immunology Winthrop-University Hospital, Stony Brook University School of Medicine, NY, USA, Mineola, NY, 37Rheumatology, Rheumatology Department, Faculty of Medicine, Cairo University, Egypt, Cairo, Egypt, 38Department of Rheumatology, Teaching hospital and University of Montpellier, France, Montpellier, France, 39Rheumatology, German Hospital, Buenos Aires, Argentina, Buenos Aires, Argentina, 40IRCCS Galeazzi Orthopedic Institute, Milan, Italy, Milan, Italy, 41Rheumatology Unit, Hospital Privado Centro Médico de Córdoba, Argentina, Córdoba, Argentina, 42Department of Clinical Sciences Malmö, Lund University, Skåne University Hospital, Rheumatology, Malmö, Sweden, Malmö, Sweden, 43Department of Rheumatology, Malmö University Hospital, Lund University, Sweden, Lund, Sweden, 44Clinic of Rheumatology, Department of Medical and Biological Sciences, University Hospital "Santa Maria della Misericordia", Udine, Italy, Udine, Italy, 45Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, Mexico, 46Federal University of São Paulo, Sao Paulo, Brazil, San Paulo, Brazil, 47Sjögren Syndrome Research Group (AGAUR), Barcelona, Spain, 48Department of Medicine, University of Barcelona, Barcelona, Spain., Barcelona, Spain

    Background/Purpose: To analyse the main characteristics of patients with primary Sjögren syndrome (SjS) with focal lymphocytic sialadenitis (FLS) unrelated to the presence of circulating anti-Ro/La…
  • Abstract Number: 591 • 2016 ACR/ARHP Annual Meeting

    Patient-Reported Outcomes for Etanercept Therapy in Adult Patients with Moderate to Severe Rheumatoid Arthritis Who Failed Adalimumab Treatment

    Louis Bessette1, Majed Khraishi2, Alan J Kivitz3, Arunan Kaliyaperumal4, Rama Grantab5, Melanie Poulin-Costello5, Maya Isaila5 and David Collier4, 1Rhumatology, Centre d’Ostéoporose et de Rhumatologie de Québec (CORQ), Québec, QC, Canada, 2Medical Consultants of West Newfoundland, Western Memorial Hospital, Corner Brook, NF, Canada, 3Altoona Center for Clinical Research, Duncansville, PA, 4Amgen Inc., Thousand Oaks, CA, 5Amgen Canada Inc., Mississauga, ON, Canada

    Background/Purpose: When a tumor necrosis factor inhibitor (TNFi) fails in a patient with moderate to severe rheumatoid arthritis (RA), new American College of Rheumatology (ACR)…
  • Abstract Number: 2687 • 2016 ACR/ARHP Annual Meeting

    Prevalence of Abortions and Fetal Atrioventricular Block in Patients with Positive ANTI-RO and ANTI-La Antibodies

    Isabel Martinez Cordellat1, Francisco Miguel Ortiz-Sanjuán1, Jose Ivorra Cortes1, Luis Gonzalez Puig1, Inmaculada Chalmeta Verdejo1, Irene Calabuig Sais2, Elena Grau Garcia1,3, Carlos Feced Olmos1, Eztizen Labrador Sanchez1, Karla Arevalo Ruales1, Rosa Negueroles Albuixech1, Jorge Fragio Gil1, Jose Luis Valero Sanz1, Cristina Alcañiz Escandell1,3, Carmen Najera Herranz1, Gema Poveda Marin1,3 and Jose Andres Roman Ivorra1,2,3, 1Department of Rheumatology, Hospital Universitario y Politecnico La Fe, Valencia, Spain, 2Universidad Católica de Valencia, Valencia, Spain, 3IIS La Fe, Valencia, Spain

    Background/Purpose:   anti-SSA/Ro and/or anti-SSB/La antibodies and to evaluate the prevalence of abortions and neonatal mortality.   We included 162 patients with positive anti-SSA/Ro and/or…
  • Abstract Number: 613 • 2016 ACR/ARHP Annual Meeting

    Immunogenicity of Anti-TNF Therapies in Patients with Inflammatory Rheumatic Diseases and Secondary Failure: A Multicentre Study of 570 Patients

    Alejandro Balsa1, Raimon Sanmarti2, José Rosas3, Susana Gomez Castro4, Ana Cabez4, Victor Martin4 and María Montoro4, 1Rheumatology, IdiPAZ, Hospital Universitario La Paz, Madrid, Spain, 2Rheumatology Department, Hospital Clínic de Barcelona, Barcelona, Spain, 3Rheumatology, Hospital Marina Baixa, Villajoyosa (Alicante), Spain, 4Pfizer, Madrid, Spain

      Abstract   Immunogenicity of anti-TNF therapies in Patients with inflammatory rheumatic Diseases and secondary failure: a multicentre study of 570 patients.   Background/Purpose: The treatment of…
  • Abstract Number: 2826 • 2016 ACR/ARHP Annual Meeting

    Clinical Utility of Circulating Anti-N-Methyl-D-Aspartate Receptor Subunits NR2A/B Antibody for the Diagnosis of Neuropsychiatric Syndromes in Systemic Lupus Erythematosus and Sjogren’s Syndrome: An Updated Meta-Analysis

    Sen Hee Tay1, Anna-Marie Fairhurst2 and Anselm Mak1, 1Division of Rheumatology, Department of Medicine, National University Hospital, National University Health System, Singapore, Singapore, Singapore, 2Singapore Immunology Network, Agency for Science, Technology and Research, Singapore, Singapore

    Background/Purpose: Neuropsychiatric (NP) events are found in patients with rheumatic diseases, commonly in systemic lupus erythematosus (SLE) and Sjögren's syndrome (SS). The standard nomenclature and…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • 5
  • …
  • 9
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology